stockrowRegencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Free cash flow margin
Regencell Bioscience Holdings Limited's free cash flow margin over the twelve months to 31 December 2025 was 0.00%. Over the past ten years it has ranged from 0.00% (fiscal 2026) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 38.1% |
| TRLV Trulieve Cannabis Corp. compare | 22.4% |
| XERS Xeris Biopharma Holdings, Inc. compare | 20.0% |
| PBH Prestige Consumer Healthcare Inc. compare | 18.4% |
| PRGO Perrigo Company plc compare | 4.11% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited | 0.00% |
| ALVO Alvotech compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue